SCHEMBL4185478

SCHEMBL4185478

CC(=O)Nc1ccc(C(C)(C)N)cc1C1=CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 16/20 0.52
HDAC1 Q13547 4/20 0.41
HDAC2 Q92769 4/20 0.41
HDAC3 O15379 2/20 0.40
CYP2C19 P33261 1/20 0.40
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL5651428 0.80 CSF1R (0.40) CSF1RHDAC1HDAC2HDAC3
SCHEMBL3070902 0.79 CSF1R (0.41) CSF1RHDAC1HDAC2HDAC3
Acetic Acid SCHEMBL5651425 0.78 CSF1R (0.39) CSF1R
SCHEMBL13147796 0.77 CSF1R (0.59) CSF1RCYP2C19KIT
SCHEMBL4192391 0.76 CSF1R (0.43) CSF1RHDAC1HDAC2HDAC3KIT
SCHEMBL3070907 0.76 PSMB5 (0.37) CSF1RHDAC1HDAC2HDAC3
SCHEMBL5655868 0.73 CSF1R (0.54) CSF1RHDAC1HDAC2HDAC3
SCHEMBL5655865 0.71 CSF1R (0.52) CSF1RHDAC1HDAC2HDAC3
SCHEMBL14383287 0.69 CSF1R (0.65) CSF1RKIT
SCHEMBL3096483 0.68 CSF1R (0.41) CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452996-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-09-27 US disclosed
EP-2021329-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-04-13 EP disclosed
US-20160046602-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-02-18 US disclosed
US-9221797-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2015-12-29 US disclosed
US-20140148448-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-8674100-B2 Inhibitors of C-FMS kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2014-03-18 US disclosed
EP-2687516-A1 Inhibitors of C-FMS Kinase Janssen Pharmaceutica N.V. (BE) 2014-01-22 EP disclosed
EP-2021329-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-02-11 EP disclosed
WO-2007124318-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249649-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249649-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885HDAC1 2158/4885HDAC2 2849/4885
US-20140148448-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885HDAC1 2158/4885HDAC2 2849/4885
US-20160046602-A1 INHIBITORS OF C-FMS KINASE FES, MUSK, FRK CSF1R 58/4885HDAC1 2158/4885HDAC2 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.